MAPKBP1

Across TCGA pan-cancer cohorts, MAPKBP1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAPKBP1 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAPKBP1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAPKBP1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where MAPKBP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.336	0.823	.002	15	view →
PDAC	OS	Quartile	II,III,IV	0.653	1.000	.004	10	view →
LSCC	DFS	Quartile	All	0.999	0.789	.012	4	view →
HNSC	DFS	Median	IV	0.889	0.719	.034	2	view →
CCRCC	OS	Median	All	0.896	0.723	.011	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAPKBP1–LUAD (DFS)

Open the LUAD breakdown →